Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alkotinib in ALK-positive NSCLC previously treated with Crizotinib
NCT04211922Phase 2Terminated
- Sponsor
- Zelgen
- Start
- Jan 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alkotinib in non-small cell lung cancer (NSCLC), sponsored by Zelgen. Primary endpoint: Objective Response Rate at 24 months. Started Jan 2020; status: terminated.
02
Drugs
alkotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04211922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211922.